Clinical Trial Update: Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI) [Phase 3]

View source ↗

Summary

This entry describes a Phase 3 clinical trial (VENP-A-QUI) evaluating azacitidine and venetoclax with or without quizartinib as first-line therapy for older/unf…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Quizartinib (Quizartinib)
• Venetoclax (venetoclax)

Snippet

Sponsor: PETHEMA Foundation | Conditions: Acute Myeloid Leukemia, Adult | Phase 3 | Status: NOT_YET_RECRUITING